
Nanomedicine is the application of nanotechnology to achieve innovation in medicine, providing new diagnostic & therapeutics tools, for earlier disease detection and new advanced / personalized treatment options. It exploits the properties of materials at the nanometric scale (10-9 m). The nanometric size is the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials used in medicine to cross natural barriers and to access new sites of drug delivery and/or to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells, improving the therapeutic outcomes and reducing side effects.
Nanomedicine aims at reaching improved therapeutic outcome and reduced side-effects;
200 billion € business worldwide in 2020, with a foreseen annual growth of 12.6% (estimated 500 billion € in 2028);
Shift from ‘simple’ chemical drugs to complex nano structures with nano-specific critical quality attributes (CQAs)
To know more about nanomedicine, have a look at the video produced by the ETPN together with the NANOMED2020 consortium.
Learn about how nanomedicine enables personalized, targeted, and regenerative medicine, bringing new drugs, treatments, and implantable devices to the forefront of healthcare. Understand the challenges of unmet medical needs and how nanomedicine offers promising solutions to a multitude of illnesses. Delve into the world of nano-enabled diagnosis, targeted drug delivery systems, and regenerative medicine, and discover how nanotechnology is already benefiting medical care in profound ways.
For a comprehensive overview of nanomedicine, its impact, applications, and the balance of its potential benefits against risks, visit ETPN's detailed guide on nanomedicine. This resource offers valuable insights into how nanomedicine is not just a futuristic vision but a present reality transforming healthcare as we know it.
The METRINO project has received funding from the European Partnership on Metrology (Grant #22HLT04), co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.